• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

日本肝细胞癌及非酒精性脂肪性肝病和非酒精性脂肪性肝炎的其他并发症:已发表作品的结构化综述

Hepatocellular carcinoma and other complications of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Japan: A structured review of published works.

作者信息

Eguchi Yuichiro, Wong Gabriel, Lee I-Heng, Akhtar Omar, Lopes Ricardo, Sumida Yoshio

机构信息

Liver Center, Saga University Hospital, Saga, Japan.

Department of Internal Medicine, Saga University, Japan.

出版信息

Hepatol Res. 2021 Jan;51(1):19-30. doi: 10.1111/hepr.13583. Epub 2020 Dec 9.

DOI:10.1111/hepr.13583
PMID:33091191
Abstract

AIMS

Hepatocellular carcinoma (HCC) is a significant cause of morbidity and mortality in Japan. As the treatment of viral hepatitis improves, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are rapidly becoming leading causes of HCC in Japan. This structured review aims to characterize the morbidity and mortality of HCC and other malignant and non-malignant complications among Japanese NAFLD and NASH patients.

METHODS

An English and Japanese structured search of published works was undertaken in PubMed, Embase, and Ichushi Web databases, identifying 6553 studies, 34 of which met predefined inclusion criteria.

RESULTS

Hepatocellular carcinoma was the most common incident malignancy among NAFLD/NASH patients, with higher incidence in patients with advanced/severe fibrosis (F3/F4) of 10.5%-20.0%. Although NASH results in a lower HCC cumulative incidence than hepatitis C virus (HCV) (11.3% vs. 30.5%), they have similar impacts on health outcomes, including overall mortality. Among Japanese NASH patients, HCC was found to be the main driver of mortality (40.0% in 2.7 years in NASH-HCC). With longer follow-up, higher mortality rates are observed in F3/4 patients: 25.0% in NASH F3/F4 versus 0.0% in NASH F0/2 over 7.7 years. The NASH-HCC patients also have a higher post-operative mortality than HCV-HCC patients. Additionally, NAFLD/NASH patients had higher rates of cardiovascular disease than non-NAFLD/NASH controls, and slightly higher rates of gastric cancer than HCV patients.

CONCLUSION

Hepatocellular carcinoma is the most common malignancy and cause of death among NAFLD/NASH patients in Japan, with higher mortality observed among those with advanced disease and complications. Early identification and effective treatments are needed.

摘要

目的

肝细胞癌(HCC)是日本发病和死亡的重要原因。随着病毒性肝炎治疗方法的改进,非酒精性脂肪性肝病(NAFLD)和非酒精性脂肪性肝炎(NASH)正迅速成为日本HCC的主要病因。本系统评价旨在描述日本NAFLD和NASH患者中HCC以及其他恶性和非恶性并发症的发病情况和死亡率。

方法

在PubMed、Embase和Ichushi Web数据库中对已发表的文献进行英文和日文的系统检索,共识别出6553项研究,其中34项符合预先设定的纳入标准。

结果

肝细胞癌是NAFLD/NASH患者中最常见的新发恶性肿瘤,在晚期/重度纤维化(F3/F4)患者中的发病率较高,为10.5%-20.0%。虽然NASH导致的HCC累积发病率低于丙型肝炎病毒(HCV)(11.3%对30.5%),但它们对健康结局的影响相似,包括总体死亡率。在日本NASH患者中,HCC被发现是死亡的主要驱动因素(NASH-HCC患者在2.7年内死亡率为40.0%)。随着随访时间延长,F3/4患者的死亡率更高:在7.7年的时间里,NASH F3/F4患者的死亡率为25.0%,而NASH F0/2患者为0.0%。NASH-HCC患者术后死亡率也高于HCV-HCC患者。此外,NAFLD/NASH患者的心血管疾病发生率高于非NAFLD/NASH对照组,胃癌发生率略高于HCV患者。

结论

肝细胞癌是日本NAFLD/NASH患者中最常见的恶性肿瘤和死亡原因,晚期疾病和并发症患者的死亡率更高。需要早期识别和有效治疗。

相似文献

1
Hepatocellular carcinoma and other complications of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Japan: A structured review of published works.日本肝细胞癌及非酒精性脂肪性肝病和非酒精性脂肪性肝炎的其他并发症:已发表作品的结构化综述
Hepatol Res. 2021 Jan;51(1):19-30. doi: 10.1111/hepr.13583. Epub 2020 Dec 9.
2
Epidemiology of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Japan: A focused literature review.日本非酒精性脂肪性肝病和非酒精性脂肪性肝炎的流行病学:文献综述
JGH Open. 2020 May 5;4(5):808-817. doi: 10.1002/jgh3.12349. eCollection 2020 Oct.
3
Non-invasive diagnosis of non-alcoholic steatohepatitis and advanced fibrosis in Japan: A targeted literature review.日本非酒精性脂肪性肝炎和晚期肝纤维化的非侵入性诊断:一项针对性文献综述
Hepatol Res. 2020 Jun;50(6):645-655. doi: 10.1111/hepr.13502. Epub 2020 May 15.
4
Hepatocarcinogenesis in non-alcoholic fatty liver disease in Japan.日本非酒精性脂肪性肝病中的肝癌发生。
J Gastroenterol Hepatol. 2013 Dec;28 Suppl 4:88-92. doi: 10.1111/jgh.12239.
5
Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies.非酒精性脂肪性肝病相关肝细胞癌的临床特征:一项人体研究综述
Clin J Gastroenterol. 2015 Feb;8(1):1-9. doi: 10.1007/s12328-014-0548-5. Epub 2015 Jan 10.
6
Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.纤维化分期而非 NASH 可预测经活检证实的非酒精性脂肪性肝病患者的死亡率和严重肝脏疾病的发生时间。
J Hepatol. 2017 Dec;67(6):1265-1273. doi: 10.1016/j.jhep.2017.07.027. Epub 2017 Aug 10.
7
Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.非酒精性脂肪性肝病相关肝细胞癌:日益受到关注。
Indian J Med Res. 2019 Jan;149(1):9-17. doi: 10.4103/ijmr.IJMR_1456_17.
8
Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH.伴有非酒精性脂肪性肝病/非酒精性脂肪性肝炎的丙型肝炎病毒相关肝硬化中的肝细胞癌的特殊组织学变异型:脂肪性肝炎相关肝细胞癌。
Am J Surg Pathol. 2010 Nov;34(11):1630-6. doi: 10.1097/PAS.0b013e3181f31caa.
9
Hepatocellular carcinoma in non-alcohol fatty liver disease - changing trends and specific challenges.非酒精性脂肪性肝病相关肝细胞癌:变化趋势与特殊挑战。
Curr Med Res Opin. 2020 Feb;36(2):235-243. doi: 10.1080/03007995.2019.1683817. Epub 2019 Nov 4.
10
The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.他汀类药物单独使用,或与吡格列酮及其他药物联合使用,用于治疗非酒精性脂肪性肝病/非酒精性脂肪性肝炎及相关心血管风险。专家小组声明。
Metabolism. 2017 Jun;71:17-32. doi: 10.1016/j.metabol.2017.02.014. Epub 2017 Mar 4.

引用本文的文献

1
Benefits in routinely measured liver function tests following bariatric surgery: a retrospective cohort study.减肥手术后常规肝功能检查的益处:一项回顾性队列研究。
J Diabetes Metab Disord. 2023 Sep 24;22(2):1763-1768. doi: 10.1007/s40200-023-01311-4. eCollection 2023 Dec.
2
Detecting advanced liver fibrosis using ultrasound shear wave velocity measurement in the general population.在普通人群中使用超声剪切波速度测量来检测晚期肝纤维化。
Quant Imaging Med Surg. 2023 Oct 1;13(10):6493-6502. doi: 10.21037/qims-23-511. Epub 2023 Aug 28.
3
Associations of non-alcoholic fatty liver disease and cirrhosis with liver cancer in European and East Asian populations: A Mendelian randomization study.
非酒精性脂肪性肝病和肝硬化与欧洲和东亚人群肝癌的关联:一项孟德尔随机研究。
Cancer Rep (Hoboken). 2024 Jan;7(1):e1913. doi: 10.1002/cnr2.1913. Epub 2023 Oct 16.
4
Palmitoyltransferase ZDHHC3 Aggravates Nonalcoholic Steatohepatitis by Targeting S-Palmitoylated IRHOM2.棕榈酰基转移酶 ZDHHC3 通过靶向 S-棕榈酰化的 IRHOM2 加重非酒精性脂肪性肝炎。
Adv Sci (Weinh). 2023 Oct;10(28):e2302130. doi: 10.1002/advs.202302130. Epub 2023 Aug 6.
5
Outcomes of fatty liver disease with and without metabolic comorbidities and risk factors for mortality.伴有和不伴有代谢合并症的脂肪性肝病的结局及死亡风险因素。
JGH Open. 2023 May 22;7(6):410-418. doi: 10.1002/jgh3.12898. eCollection 2023 Jun.
6
Prognosis after hepatic resection of patients with hepatocellular carcinoma related to non-alcoholic fatty liver disease: meta-analysis.非酒精性脂肪性肝病相关肝细胞癌患者行肝切除术后的预后:荟萃分析。
BJS Open. 2023 Jan 6;7(1). doi: 10.1093/bjsopen/zrac167.
7
Metabolic Risk Factors for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: A Prospective Study.非酒精性脂肪性肝病患者肝细胞癌的代谢危险因素:一项前瞻性研究
Cancers (Basel). 2022 Dec 17;14(24):6234. doi: 10.3390/cancers14246234.
8
Quantification of DNA methylation for carcinogenic risk estimation in patients with non-alcoholic steatohepatitis.非酒精性脂肪性肝炎患者致癌风险评估的 DNA 甲基化定量。
Clin Epigenetics. 2022 Dec 5;14(1):168. doi: 10.1186/s13148-022-01379-4.
9
Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: Current Progresses and Challenges.非酒精性脂肪性肝病中的肝细胞癌:当前进展与挑战
J Clin Transl Hepatol. 2022 Oct 28;10(5):955-964. doi: 10.14218/JCTH.2021.00586. Epub 2022 May 18.
10
Two differentially methylated region networks in nonalcoholic fatty liver disease, viral hepatitis, and hepatocellular carcinoma.非酒精性脂肪性肝病、病毒性肝炎和肝细胞癌中两个差异甲基化区域网络。
BMC Gastroenterol. 2022 Jun 2;22(1):278. doi: 10.1186/s12876-022-02360-4.